OSE Immunotherapeutics Announces Positive Results in Ovarian Cancer Trial

OSE Immunotherapeutics has revealed favorable topline outcomes from the Phase 2 TEDOVA trial. Conducted on 185 patients with platinum-sensitive recurrent ovarian cancer, the study explored the effects of Tedopi®, with and without pembrolizumab, versus supportive care. Results demonstrated a significant 4.1-month median progression-free survival for the Tedopi® and pembrolizumab combination compared to 2.8 months for the control group.

This trial marks a significant step in addressing unmet medical needs in ovarian cancer treatment. Alexandra Leary, MD, highlighted the enhanced survival rates as a remarkable achievement. OSE will discuss the full implications of these findings during the ASCO 2026 Annual Meeting and a subsequent webcast.